Perioperative and Adjuvant Immunotherapy in Lung Cancer: New Strategies, Biomarkers, Patient Selection and Toxicity Management
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 83
Special Issue Editors
Interests: lung cancer; precision oncology; immunotherapy
Special Issues, Collections and Topics in MDPI journals
2. Department of Radiation Oncology, GenesisCare, Hospital Universitario San Francisco de Asís y Hospital Universitario La Milagrosa, 28002 Madrid, Spain
Interests: radiation oncology; chemotherapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals
2. Thoracic Surgery Department, Hospital de la Santa Creu i Sant Pau & Hospital del Mar, Barcelona, Spain
3. TRAIL Research Group, Intitut de Recerca de Sant Pau, Barcelona, Spain
Interests: lung cancer; thoracic surgery; VATS
Special Issue Information
Dear Colleagues,
Perioperative and adjuvant immunotherapy are reshaping the standard of care for early-stage non-small-cell lung cancer (NSCLC), offering the possibility to increase the proportion of cured patients and achieve long-term survival. Recent landmark trials, such as CheckMate 816, KEYNOTE-671, and IMpower010, among others, have demonstrated significant improvements in disease-free and overall survival. However, important questions remain regarding optimal treatment strategies, patient selection, integration with other modalities, and the management of immune-related and treatment-related toxicities and sequelae in this potentially curable setting.
This Special Issue aims to bring together the latest clinical, translational, and real-world evidence in the following areas:
- New perioperative and adjuvant immunotherapy strategies in NSCLC.
- Patient selection for each treatment approach.
- Biomarkers to predict efficacy and/or toxicity and guide immunotherapy strategy selection.
- Combination approaches with antibody–drug conjugates (ADCs), chemotherapy, targeted therapy, or radiotherapy.
- Mechanisms of resistance and strategies to overcome them in early-stage disease.
- Management and prevention of immune-related and other treatment-related toxicities.
- Surgical considerations in patients receiving perioperative immunotherapy.
- Integration of artificial intelligence and omics-based tools for response and toxicity prediction.
We welcome original research articles, reviews, and communications addressing these topics from a clinical, translational, or multidisciplinary perspective.
We look forward to your contributions to advance the field and refine the role of perioperative and adjuvant immunotherapy in lung cancer.
Dr. Xabier Mielgo Rubio
Dr. Felipe Couñago
Dr. Juan Carlos Trujillo-Reyes
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small-cell lung cancer (NSCLC)
- immunotherapy
- neoadjuvant treatment
- adjuvant treatment
- perioperatory treatment
- chemotherapy
- surgery
- radiotherapy
- toxicity
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
